KCSOA makes a 3rd attempt to secure incorporation

The success lies in recruiting solo-CSOs, who make up 70% of the industry

Refining organization and improving strategic business plans…speeding up to reapply for approval in the second half

70% of registered CSOs are solo-CSOs…"Securing individual membership remains a future challenge"

Korea Contract Sales Organization Association (KCSOA)

The Korea Contract Sales Organization Association (KCSOA) is attempting a third time to secure official incorporation from regulatory authorities. Industry insiders indicate that the primary hurdle to obtaining approval will depend on the association's ability to recruit "solo-operator CSOs", individual entrepreneurs, and freelancers who currently represent more than 70% of all registered Contract Sales Organizations (CSOs) in South Korea.

According to biopharmaceutical industry sources on the 6th, KCSOA is actively preparing to apply for official corporate body status. The association is reportedly refining its articles of incorporation and strategic business plans, which the Ministry of Health and Welfare (MOHW) cited as deficiencies in two prior rejections. KCSOA aims to finalize its organizational restructuring, including the appointment of a new executive board, within this month before resubmitting its formal application for incorporation to the MOHW in the second half of this year.

This round of attempt is largely attributed to a shifting regulatory stance within the MOHW. The ministry recently acknowledged the need to establish an official communication channel with the CSO sector, expressing alignment with the fundamental need for a formalized association. However, the regulatory body also maintained a strict stance on statutory compliance, clarifying that it will evaluate any resubmission in strict accordance with relevant administrative regulations once the previously insufficient documentation is completely rectified.

Industry analysts note that securing corporate body status is a foundational step toward expanding KCSOA’s official mandate. Once recognized as a legal entity by the MOHW, the association can serve as an accredited counterparty for government consultations. This would enable the organization to systematically drive industry-wide continuing education, regulatory policy initiatives, and self-regulatory compliance programs on behalf of the sector. Both the ministry and the industry share a consensus on the urgency of an official representative body as administrative demands rise, driven by mandatory compliance workflows such as annual 8-hour continuing education requirements, spend transparency reporting, and the oversight of multi-tier consignment and re-consignment contracts.  

'Industry representativeness' is a critical benchmark for achieving official incorporation. During the administrative review process for non-profit organizations, a pivotal evaluation factor is whether the applicant represents the broader sector comprehensively, rather than disproportionately favoring a specific sub-segment or a select group of corporate entities.

In particular, bringing solo-operator CSOs is considered the decisive variable in establishing true industry-wide representation. Since the implementation of the mandatory CSO Registration System in October 2024, approximately 15,000 entities have secured registration certificates from local municipal governments. Both state regulators and market insiders estimate that roughly 70% of these registrations (equivalent to nearly 10,000 operators) comprise individual business owners or freelancers acting as solo CSOs.

However, significant practical barriers remain, as the association's current membership architecture is heavily weighted toward larger corporate CSOs. In standard pharmaceutical promotion models, a drug manufacturer enters into a primary consignment contract with a corporate CSO, which subsequently subcontracts operational volume to independent solo CSOs through reconsignment agreements. Because solo operators rely directly on corporate CSOs for their project pipelines, market analysts suggest that these independent freelancers see little tangible commercial incentive to join the association.  

The perception that membership yields minimal practical advantages while increasing administrative burdens also impedes the recruitment of individual members. A biopharmaceutical industry source noted that individual freelancers often display aversion to formalizing their status or exposing their identities through association registries. The source added that concerns over membership fees, coupled with apprehensions that individual voices might be marginalized within a corporate-dominated governance structure, further exacerbate this resistance.

Despite these hurdles, voices within the CSO sector consistently maintain that establishing an official, recognized association is essential to the industry’s long-term evolution.  

The CEO of another prominent CSO noted, "The MOHW's shifting stance on the necessity of a formalized association is a highly welcome development. An official incorporation will empower the organization to fulfill its intended institutional mandates," and added, "There is strong consensus within the CSO community to cultivate a clean, compliant distribution ecosystem."

The CEO further stated, "The outcome depends on how successfully the association can integrate solo CSOs into the institutional framework," and added, "A failure to encourage individual membership will inherently restrict both the legal representativeness and the association's self-regulatory capabilities."

The CEO added, "To my knowledge, previous rejections were primarily affected by quantitative shortfalls such as total membership headcount and asset thresholds," and concluded, "MOHW should evaluate the association's qualitative operational capabilities and its institutional commitment to compliance alongside headcount and membership fee size."